Valuation Enlivex

Stocks

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-14 EDT			5-day change	1st Jan Change
6.050 ^USD	-9.30%		-18.35%	-42.64%

06-15	Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis	MT
06-01	Enlivex Ltd. Presents Durable 6-Month Efficacy Data For Allocetra In Knee Osteoarthritis Phase IIa Trial	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Market Cap ¹	114.6	72.5	50.22	25.73	166.9	97.22	-
Change	-	-36.72%	-30.73%	-48.77%	548.82%	-41.76%	-
Enterprise Value (EV)	114.6	72.5	50.22	25.73	166.9	97.22	97.22
Change	-	-36.72%	-30.73%	-48.77%	548.82%	-41.76%	0%
P/E	-7.72x	-2.33x	-1.73x	-1.6x	0.03x	-5.04x	-4.48x
PBR	-	-	-	-	-	-	-
PEG	-	-0x	0.22x	0x	-0x	0x	-0.4x
Capitalization / Revenue	-	-	-	-	-	-	-
EV / Revenue	-	-	-	-	-	-	-
EV / EBITDA	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	-0x	-0x	-0x	-4.86x	-3.89x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-
EPS ²	-12.15	-25.35	-23.4	-10.95	382.2	-1.2	-1.35
Distribution rate	-	-	-	-	-	-	-
Net sales ¹	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
EBIT ¹	-19.29	-25.8	-29.4	-15.89	-15.03	-20	-25
Net income ¹	-14.47	-31.06	-29.07	-15.01	1,236	-20	-25
Net Debt	-	-	-	-	-	-	-
Reference price ²	93.750	59.062	40.500	17.550	10.548	6.050	6.050
Nbr of stocks (in thousands)	1,222	1,227	1,240	1,466	15,825	16,070	-
Announcement Date	4/29/22	3/31/23	3/29/24	3/31/25	3/25/26	-	-